Skip to main navigation Skip to search Skip to main content

Unified epigenomic, transcriptomic, proteomic, and metabolomic taxonomy of Alzheimer’s disease progression and heterogeneity

  • Yasser Iturria-Medina*
  • , Quadri Adewale
  • , Ahmed F. Khan
  • , Simon Ducharme
  • , Pedro Rosa-Neto
  • , Kieran O’Donnell
  • , Vladislav A. Petyuk
  • , Serge Gauthier
  • , Philip L. de Jager
  • , John Breitner
  • , David A. Bennett
  • *Corresponding author for this work
  • McGill University
  • McConnell Brain Imaging Centre, Montreal Neurological Institut, McGill University, Montreal, Québec, Canada
  • Ludmer Centre for Neuroinformatics and Mental Health
  • Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, Canada
  • Yale University School of Medicine
  • Pacific Northwest National Laboratory
  • Columbia University Medical Center
  • Douglas Hospital Research Center
  • Rush University

Research output: Contribution to journalArticleAcademicpeer-review

22 Downloads (Pure)

Abstract

Alzheimer’s disease (AD) is a heterogeneous disorder with abnormalities in multiple biological domains. In an advanced machine learning analysis of postmortem brain and in vivo blood multi-omics molecular data (N = 1863), we integrated epigenomic, transcriptomic, proteomic, and metabolomic profiles into a multilevel biological AD taxonomy. We obtained a personalized multilevel molecular index of AD dementia progression that predicts severity of neuropathologies, and identified three robust molecular-based subtypes that explain much of the pathologic and clinical heterogeneity of AD. These subtypes present distinct patterns of alteration in DNA methylation, RNA, proteins, and metabolites, identifiable in the brain and subsequently in blood. In addition, the genetic variations that predispose to the various AD subtypes in brain predict distinct spatial patterns of alteration in cell types, suggesting a unique influence of each putative AD variant on neuropathological mechanisms. These observations support that an individually tailored multi-omics molecular taxonomy of AD may represent distinct targets for preventive or treatment interventions.
Original languageEnglish
Article numbereabo6764
JournalScience advances
Volume8
Issue number46
DOIs
Publication statusPublished - 16 Nov 2022
Externally publishedYes

Fingerprint

Dive into the research topics of 'Unified epigenomic, transcriptomic, proteomic, and metabolomic taxonomy of Alzheimer’s disease progression and heterogeneity'. Together they form a unique fingerprint.

Cite this